Proton / Particle Therapy

Proton Therapy Partners (PTP), formed in 2018, collaborates with healthcare providers to build, own and operate proton therapy centers. The Company’s business model allows healthcare providers to build these centers in an efficient, cost-effective and patient-centric manner.

PTP fuses innovative medical technology, industry expertise and an efficient financial model to create a network of proton therapy centers with the ability to reach more patients in rural and urban markets.

Proton Therapy

The Most Advanced Tool Available to Radiation Oncologists for the Treatment of Cancerous Tumors


  • ~ 1.8mm U.S. patients are diagnosed with cancer each year.
  • The rate of new cases of cancer is 442 per 100,000 per year.
  • Approximately 40% of men and women will be diagnosed with cancer at some point in their lifetime.







  • Advanced form of external radiation therapy.
  • Uses high-energy proton beams rather than traditional x-ray beams to irradiate a  tumor.
  • Absorbed dose of protons increases gradually as it enters the body and rises to a peak  when the protons are slowed  down and delivered which  significantly reduces the  negative effects on healthy  tissue, critical structures and organs at risk.


  • There is no “exit dose” which significantly reduces the negative effects on healthy tissue including surrounding critical structures.
  • Gantry and robotic couch rotation allows for all needed clinical beam angles to be delivered.
  • Image guidance, including cone beam CT and in-room diagnostic CT, ensures accurate patient positioning, precise beam delivery and adaptive therapy applications.


  • Added proton precision reduces the risk of damage to surrounding healthy tissues and organs reducing treatment related side effects.
  • Lower integral radiation dose reducing the long-term risk of secondary cancer.
  • Radiation oncologists can increase the dose to the tumor while reducing any  interaction with surrounding  healthy tissue organs at risk.
  • Less toxic treatment allows for more aggressive treatments and improved patient outcomes.


  • ~ 4.4% reduction in overall cost of care due to lower ancillary care utilization.
  • 2/3 reduction of severe side effects within 90 days of treatment.
  • 31% relative reduction in occurrence of secondary cancers after treatment.
  • Commercial payor landscape has become more compelling due to clinical  efficacy and  considerations.

© 2024 Infinity Oncology Solutions